The MHRA has just approved the Novavax COVID-19 vaccine, Nuvaxovid, for use in people aged 18 and over for a first and second dose. Novavax have put forward some experts who can answer journalists questions about the vaccine, and the MHRA approval.
Prof Paul Heath, Principal Investigator of the UK arm of the Novavax vaccine trial, and Professor of Paediatric Infectious Diseases and Director of the Vaccine Institute, St George’s, University of London
Filip Dubovsky, Chief Medical Officer, Novavax
Silvia Taylor, Head of Corporate Affairs, Novavax
This Briefing was accompanied by an SMC Roundup of Comments.